Cumberland Pharmaceuticals has expanded its portfolio over the last few months. At the end of 2016, the Nashville-based specialty pharmaceutical company entered into an agreement to acquire the exclusive U.S. rights to Nordic Group B.V.'s innovative injectable methotrexate product line, which are focused on the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. Cumberland will be responsible for the FDA submission and registration for the products.

Last month, Cumberland and Clinigen Group plc announced an exclusive agreement to commercialize the oncology support drug Totect^® (dexrazoxane hydrochloride). This is the second product Clinigen has licensed to Cumberland under the strategic alliance established in 2015. Totect is an FDA-approved emergency oncology intervention, which is indicated to reverse the toxic effects of anthracycline chemotherapy in case of extravasation.